Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074568 · ClinicalTrials.gov registry record
Scleroderma Registry
A clinical trial of Systemic Sclerosis and Scleroderma, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- Completed
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT00074568 is a study of Systemic Sclerosis and Scleroderma that has completed, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The registered enrollment target is 5,000 participants, above the 87-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (5647% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00074568, a study of Systemic Sclerosis and Scleroderma, has completed, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- COMPLETED
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Scleroderma is likely caused by a combination of factors, including an external trigger (infection or other exposure) and a genetic predisposition. The Scleroderma Registry will conduct genetic analyses for disease-related genes in patients with scleroderma and their family members (parents, brothers, and sisters).
Conditions Studied
Study Locations (1)
Texas
- University of Texas - Houston Medical School - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2000-09 |
| Est. Completion | 2022-01 |
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)93 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00074568
The ClinicalTrials.gov registry entry for NCT00074568 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 87-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (5647% higher). The listed sponsor is National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Systemic Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT00074568 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00074568 about?
NCT00074568 is a clinical study titled "Scleroderma Registry". Scleroderma is likely caused by a combination of factors, including an external trigger (infection or other exposure) and a genetic predisposition. The Scleroderma Registry will conduct genetic analyses for disease-related genes in patients with scleroderma and their family members (parents, brother...
What is the current status of trial NCT00074568?
This trial is currently completed. The enrollment target is 5,000 participants. The study started on 2000-09. Estimated completion is 2022-01.
What conditions does trial NCT00074568 study?
This clinical trial studies the following conditions: Systemic Sclerosis, Scleroderma.
Who is sponsoring clinical trial NCT00074568?
This trial is sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00074568 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
RECRUITING · NA
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
New Orleans Pulmonary Hypertension Biobank
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.